Anticoagulants, commonly referred to as blood thinners, are chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, blood transfusion bags, and dialysis equipment.
Novel Oral Anticoagulants (NOACs) have major pharmacologic benefits over warfarin, which is a vitamin K antagonist, together with the rapid onset/offset of action, few drug interactions and predictable pharmacokinetics. Warfarin has a limited therapeutic window that can be strike by factors such as diet and enabling patients on warfarin to monitor their INR regularly. Novel oral anticoagulant (NOACs) is the top performing segment as an alternative to anticoagulant. Increasing number of patients with lifelong medical aid therapy, growing prevalence of blood vessel thromboembolism, arrhythmia, and stroke, acceptance of NOAC’s is raising revenue in the market, rising outpatient anticoagulation therapy, increasing number of pipeline products under clinical trials and rising heparin trade spurring the growth of anticoagulation therapy market. However, high cost of developing drugs and risk of malfunctions like increased bleeding is main issue with newer agents are expected to impact the target market negatively.

Market Analysis and Insights: Global Anticoagulation Therapy Market
The global Anticoagulation Therapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anticoagulation Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anticoagulation Therapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anticoagulation Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anticoagulation Therapy market.

Global Anticoagulation Therapy Scope and Market Size
Anticoagulation Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anticoagulation Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
NOACs
Warfarin

Segment by Application
Hospital Associated Clinics
Independent Clinics
Pharmacy-Based Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
CH Boehringer Sohn
Bristol-Myers Squibb
Johnson＆Johnson
Pfizer
Daiichi Sankyo
Portola Pharmaceuticals
Roche
Abbott